• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library

    Enforcement Report - Week of December 13, 2023

    FDA

    Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization

    FDA

    Enforcement Report - Week of September 27, 2023

    FDA

    Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization

    FDA

    Enforcement Report - Week of October 5, 2022

    FDA

    Enforcement Report - Week of June 15, 2022

    FDA

    Health Canada Issues Recall of Novartis Pharmaceuticals Canada`s BEOVU (brolucizumab)eutica

    HEALTH CANADA

    Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL

    FDA

    Health Canada Issues Recall of Novartis Pharmaceuticals` Xolair (Omalizumab) Powder For Solution

    HEALTH CANADA

    Enforcement Report - Week of May 29, 2019

    FDA

    Novartis Issues Voluntary Nationwide Recall of Promacta® 12.5 mg for Oral Suspension

    FDA

    TGA Issues Recall of Mylan Australia`s Dilart and Dilart HCT (valsartan)

    TGA

    Sandoz Recalls Losartan Potassium & Hydrochlorothiazide Due to Trace NDEA

    FDA

    FDA updates on angiotensin II receptor blocker (ARB) recalls

    FDA

    Enforcement Report - Week of May 3, 2017

    FDA

    Novartis Initiates Class III Recall of Foradil Aerolizer (formoterol fumarate inhalation powder) Due to Failed Stability Specification

    FDA

    Actavis High Blood Pressure Drug Fails to Win U.S. Approval

    BLOOMBERG

    HC Reserves Order on Novartis-Cipla Drug Dispute

    Novartis Announces Safety and Efficacy Benefit of Jakavi® in Global Clinical Trial of Over 1,000 Patients with Myelofibrosis

    NOVARTIS WEBSITE

    J&J Discount Offer Wins NICE Over to New Use for Stelara

    FIERCE PHARMA

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.